ClinicalTrials.gg
CompletedNCT02186483Updated Mar 29, 2018

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

A Phase 1 interventional study of Metformin and Rosuvastatin in Hyperlipidemia and Diabetes, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Hyperlipidemias.

Enrollment
27th of 30
24 · median 114
Started
2014
with 3 others
Phase 1
7 of 30
none open now
Registered
14th of 30
by date
Lead sponsor
2 of 30
Jeil Pharmaceutical Co., Ltd.

Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 27th largest by enrollment, is one of 4 that started in 2014, is one of 7 in phase 1, and was the 14th registered.

Hyperlipidemias

863 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rosuvastatin in Hyperlipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetic drug interaction between Metformin and Rosuvastatin in healthy male volunteers.

Read the detailed description

Drug-drug Interaction Following Co-administration of Metformin and Rosuvastatin in Healthy Male Volunteers

03

Conditions studied

  • Hyperlipidemia
  • Diabetes
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19\~55 years healthy male
  • measurement 19.0kg/m\^2\~ 28.0kg/m\^2
  • Signed form from to participate voluntarily and to comply with the trial requirements.

Exclusion criteria

Exclusion Criteria:

  • History of kidney, liver, gastro-intestinal system, cardiovascular system, respiratory system, tumor or blood disorders, nervous system, immune system, endocrine disorders, cardiovascular diseases, mental disorders (mood disorders, obsessive-compulsive disorder, etc.)
  • SBP>140mmHg or \<90mmHg, DBP>90mmHg or \<60mmHg.
  • An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
  • History of drug abuse
  • A alcohol consumer(alcohol>140g/week) or smoker(cigarette>10 cigarettes/day) reaction in history of drugs or specific drugs(aspirin, antibiotics)
  • Administrated investigational product in a previous clinical trial within 60 days of the screening day in this study.
  • Administrated drugs which can inhibit or induce OCT2, OATP1B1 transporter within 30 days of the screening day in this study.(ex: proton pump inhibitor, rifampicin)
  • \<60mL/min
  • Donated blood within 60 days prior to the screening day or apheresis blood within 30 days prior to the screening day .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Metformin

    Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration

    Drug: Metformin · Drug: Rosuvastatin · Drug: Metformin and Rosuvastatin

  • Experimental
    Rosuvastatin

    Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin

    Drug: Metformin · Drug: Rosuvastatin · Drug: Metformin and Rosuvastatin

  • Experimental
    Co-administration

    Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin

    Drug: Metformin · Drug: Rosuvastatin · Drug: Metformin and Rosuvastatin

Interventions

  • Metformin,1000mg, once daily

    Also known as: Glucodown OR SR tablet

  • Rosuvastatin, 20 mg, once daily

    Also known as: Crestor tablet

  • DrugMetformin and Rosuvastatin

    Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily

    Also known as: Glucodown OR SR tablet and Crestor tablet

06

What researchers measure

Primary outcomes

  1. Cmax,ss, AUCτ

    Time frame: 32h

Secondary outcomes

  1. Tmax,ss

    Time frame: 32h

  2. t1/2

    Time frame: 32h

  3. Cmin,ss

    Time frame: 32h

  4. CL/Fss

    Time frame: 32h

  5. Vd/Fss

    Time frame: 32h

07

Study locations

1 site
  • Samsung Medical Center(SMC)
    Seoul, Gangnam-Gu 135-710, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 10, 2014
Start
Aug 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02186483
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Aug 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Mar 29, 2018

Study contacts

Jung-ryul Kim, MD, Ph.D
principal investigator · Samsung Medical Center(SMC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Rosuvastatin

Start the discussion